A Multi-centre, Prospective, Observational Study on Effectiveness and Safety of ZOLADEX® (goserelin acetate implant) 10.8 mg and ZOLADEX® (goserelin acetate implant) 3.6 mg in Chinese Patients with Localized or Locally Advanced Hormonal Treatment -naïve Prostate Cancer

Trial Identifier: D8664R00001
Sponsor: AstraZeneca
NCTID:: NCT03193060
Start Date: September 2017
Primary Completion Date: December 2019

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China, Beijing Beijing, China
China, Guangdong Guangzhou, Guangdong, China
China, Guangdong Huizhou, Guangdong, China
China, Guangdong Jiangmen, Guangdong, China
China, Guangdong Meizhou, Guangdong, China
China, Guangdong Zhuhai, Guangdong, China
China, He Bei Shi Jiazhuang, He Bei, China
China, Hebei Langfang, Hebei, China
China, Heilongjiang Harbin, Heilongjiang, China
China, Henan Zhengzhou, Henan, China
China, Hubei Wuhan, Hubei, China
China, Inner Mongolia Baotou, Inner Mongolia, China
China, Jiangsu Nanjing, Jiangsu, China
China, Ningxia Yinchuan, Ningxia, China
China, Shandong Jinan, Shandong, China
China, Shandong Yantai, Shandong, China
China, Shanghai Shanghai, China
China, Shanxi Xi'an, Shanxi, China
China, Sichuan Chengdu, Sichuan, China
China, Xinjiang Urumqi, Xinjiang, China
China, Zhejiang Hangzhou, Zhejiang, China
China, Zhejiang Jiaxing, Zhejiang, China
China, Zhejiang Ningbo, Zhejiang, China